Investment

Human antibodies
#Antibodies #Immunotherapy #Investment #Start-ups

Start-up focusses on human-derived antibody drugs

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More

#News #Start-up Zone

Testing antiviral vaccines in the lab
#Antivirals #Clinical research #Investment #Pandemic prevention

$12 million awarded for the development of antiviral therapies

Three institutions have received a share of $12 million for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.  The money was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID may… Read More

#News

Using C. elegans to screen compounds
#C elegans #Drug screening #Drug toxicity #Financing #Investment #Research services

Anti-ageing research company secures investment

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by… Read More

#Business & Investment #News

Biosafety testing
#Biosafety testing #Expansion #Investment #Merck #US

Merck invests €290 million in biosafety testing

Merck has invested more than €290 million in its biosafety testing capacity at Rockville, Maryland, in the US.   The company says the investment will significantly increase the company’s ability to conduct biosafety testing and analytical development services, critical to the drug development and commercialisation process.  “These significant investments in Rockville… Read More

#Business & Investment #News

#Biotechnology #Disease networks #Drug targets #Financing #Investment #Precision medicine #Start-ups

New biotech aspires to reveal insights into disease biology

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More

#News #Start-up Zone

Rishi Sunak presenting the UK budget
#Academy of Medical Sciences #BioIndustry Association #Biomedical research #Cancer Research UK #Economy #Funding #Investment #UK budget #UK economy #UK government

UK biomedical organisations warn against research cuts 

Ahead of the UK Government’s Autumn Statement on Thursday, leading biomedical research companies, charities and institutions have called for the Chancellor to place medical and health research at the heart of plans for growth.  The letter has been signed by the Academy of Medical Sciences, Pfizer, Wellcome,… Read More

#News

Doctor and patient
#Cell and gene therapy #Investment #Point of care services #United States

CGT company secures investment for point of care services

Orgenesis has agreed up to $50 million investment from Metalmark Capital in its US-based point of care services subsidiary, Morgenesis.  The investment will consist of an upfront investment of $30 million and two future investments of $10 million each, subject to the achievement of certain milestones.  Morgenesis will use the… Read More

#Business & Investment #News

Builders checking plans
#Biologics / Biotechnology #Biotech hubs #Cell and gene therapy #Drug discovery #Expansion #Investment #Laboratory #Manufacturing

Space to innovate: where are biotech’s top expansions?

Expansions to laboratory space throughout the drug discovery industry can only be a good thing – new centres of innovation will bring more space to grow, more advanced technologies, improved sustainability and new employment opportunities.  While there have been a significant number of new facilities built in the US,… Read More

#Editor's Choice #News

Scientist filling test tubes in biotechnologymlab
#Biologics / Biotechnology #EIT Health #European Commission #Investment #Regulatory #Start-ups

Partnership supports biotech start-ups on journey to market

ProductLife Group has been chosen as the exclusive Privileged Partner for Regulatory & Compliance services by EIT Health’s Venture Centre of Excellence (VCoE). The partnership means EIT Health will… Read More

#News

UK on global map
#BioIndustry Association #Biologics / Biotechnology #Equity finance #Finance #Fundraising #Investment #Life sciences #Market reporting #Private investment #Seed funding #UK

UK remains strongest biotech hub in Europe despite general decline

After a disappointing start to the year, the last few months have seen a boost to fundraising for UK biotech companies. DDW’s Diana Spencer unpacks the Q3 figures and annual predictions from the BioIndustry Association1.  While 2021 was the highest year on record for investments into UK biotech and life… Read More

#Business & Investment #Exclusive Content #Market Reports

Stem cell research
#Blood cell production #Immunity #Investment #Stem cell rejuvenation #Stem cells

Stem cell rejuvenation startup secures investment 

Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital.  Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system.   Ageing causes stem cells to lose their normal structure by increased… Read More

#Business & Investment #News

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

#AI #Deep learning #Drug discovery #Investment #Machine learning

€30 million raised to advance AI enabled drug discovery pipeline 

Aqemia has raised €30 million in a Series A funding round to further support its mission to massively scale drug discovery through a first-in-class technological platform combining quantum-inspired physics and machine learning.  The financing was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of Elaia… Read More

#Business & Investment #News

The microbiome
#Gut microbiome #Investment #Probiotics

Seventure Partners invests to “unleash the potential of microbiome science”

Danish microbiome research company Clinical Microbiomics has received a €10 million investment from ‘Health for Life Capital II’, managed by Seventure Partners. Microbiome venture capitalists Seventure Partners have backed growth companies in the microbiome field with funding through ‘Health for Life I’ and ‘Health for Life II’ since 2013. Microbiome… Read More

#Business & Investment #News

Mosquito
#Biotechnology #Investment #Malaria

Malaria specialists secure $1.5m investment round  

US biotechnology start-up LivFul has secured a $1.5m investment to expand its work saving lives from malaria and other insect-borne diseases, and to support the company’s growth plans.    The company’s major markets are now opening up following the pandemic, with interest in Livful’s Enhanced Insect Repellent ramping up. Livful is… Read More

#Business & Investment #News

#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Investment #Leukaemia #Plecoid

Pleco Therapeutics raises €17.3m to progress leukaemia drug

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a… Read More

#News